Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics

The goal of the study is to develop an algorithm that associates between biomarkers detected in biospecimen of NSCLC patients, and their:

• Response to treatment
• Clinical benefit parameters such as PFS and OS.
• Adverse events to immune check inhibitor therapy
• Biological mechanisms involved in response or resistance to immune check inhibitor therapy.

Patients will provide plasma, PBMCs, stool and tissue samples (where applicable) before and during treatment.

Clinical data, including disease history, given treatment, response evaluation and adverse events to the treatment will be recorded.

Samples will be analysed as follows -

• Proteomic features (Plasma proteomics)
• Epigenetic patterns (cell free DNA)
• ctDNA mutation analysis
• PBMC subpopulations
• Microbiome profiling (Stool)

Inclusion criteria

• Provision of informed consent prior to any study-specific procedures.
• Male or female aged at least 18 years.
• ECOG PS - 0/1-2.

Exclusion criteria

• Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of treatment.
• Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.